1 September 2023 - The September 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The September issue of the Schedule includes a few major new/revised listings:

• Azacitidine (Onureg) - new indication
• Patiromer sorbitex calcium (Veltassa) - new medicine
• Pembrolizumab (Keytruda) - new indication
• Zanubrutinib (Brukinsa) - new indication

Read Summary of PBS changes